Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01551303 · ClinicalTrials.gov registry record · NA
Effect of Intranasal Neuropeptide on Emotion Perception in Trait Anxiety
A NA study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- NA
- Development phase
- 47
- Enrollment target
NCT01551303: Completed NA study, sponsored by Massachusetts General Hospital.
NCT01551303 is a NA study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 47 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01551303, a NA study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- NA
- Development phase
- 47 participants
- Enrollment target
Study Summary
The purpose of this study is to learn more about how emotional processing may be affected by a hormone called oxytocin. Oxytocin is a hormone that occurs naturally in the body, and may play an important role in the way that the brain perceives information.
Interventions
- DRUG Placebo
- DRUG Oxytocin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2009-02 |
| Est. Completion | 2012-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01551303
The ClinicalTrials.gov registry entry for NCT01551303 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01551303 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01551303 about?
NCT01551303 is a clinical study titled "Effect of Intranasal Neuropeptide on Emotion Perception in Trait Anxiety". The purpose of this study is to learn more about how emotional processing may be affected by a hormone called oxytocin. Oxytocin is a hormone that occurs naturally in the body, and may play an important role in the way that the brain perceives information.
What is the current status of trial NCT01551303?
This trial is currently completed. It is a NA study. The enrollment target is 47 participants. The study started on 2009-02. Estimated completion is 2012-12.
What interventions are being tested in trial NCT01551303?
The interventions under investigation include: Placebo (DRUG), Oxytocin (DRUG).
Who is sponsoring clinical trial NCT01551303?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.